Asset profile
RC28-E
Protein / enzyme therapeutic
Evidence outlook · registrational
Age-Related Macular Degeneration: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT04270669: The study was open-label and non-randomized, included 37 participants across three dose groups, and had no placebo or active comparator. Its primary clinical endpoint was change in ETDRS best-corrected visual acuity at weeks 12 and 48, but the results and whether the endpoint was met are unavailable.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.